Petrelintide Yields Up to 10.7% Weight Loss in Phase 2 Trial, Study Finds
- Petrelintide, an investigational human amylin analogue developed for weight management, achieved mean weight reductions ranging from -8.7% to -10.7% by week 42 in a phase 2 trial, according...
- At the primary end point of week 28, mean weight change ranged from -7.9% to -9.8% across active petrelintide treatment arms, compared with a -1.7% change in the...
- Nausea emerged as the primary gastrointestinal signal, occurring in 20% of participants receiving petrelintide compared with 6% receiving a placebo.
Petrelintide, an investigational human amylin analogue developed for weight management, achieved mean weight reductions ranging from -8.7% to -10.7% by week 42 in a phase 2 trial, according to findings published in Lancet Diabetes Endocrinol on September 29, 2026.
Petrelintide Reduces Weight More than Placebo
At the primary end point of week 28, mean weight change ranged from -7.9% to -9.8% across active petrelintide treatment arms, compared with a -1.7% change in the placebo group, with all comparisons reaching statistical significance at P < .0001. By week 42, reductions extended to -8.7% to -10.7%, while the placebo group showed no further change. The study authors noted that the 5.0-mg, 7.0-mg, and 9.0-mg doses produced similar weight loss results, pointing to a plateau effect. Exploratory end points at week 42 showed that 34% to 56% of participants receiving petrelintide lost at least 10% of their body weight, versus 9% in the placebo group.
Nausea Occurs Primarily During Dose Escalation
Nausea emerged as the primary gastrointestinal signal, occurring in 20% of participants receiving petrelintide compared with 6% receiving a placebo. Of those nausea cases, 80% were classified as mild, and 73% occurred during the dose escalation phase. Rates for diarrhea at 7% versus 7% and constipation at 7% versus 4% remained low. Vomiting was infrequent overall at 3% versus 6%, though the 9.0-mg dose group reached 9%. Permanent discontinuation due to gastrointestinal events occurred in just 1% of participants, and 2% required dose reductions, while 88% to 98% successfully reached their target maintenance dose.
Cardiometabolic Markers and Additional Adverse Events
Treatment with petrelintide correlated with reductions in high-sensitivity C-reactive protein of up to 41% compared with a 6% change for placebo, along with systolic blood pressure reductions of 2.8 to 4.0 mm Hg and greater increases in high-density lipoprotein cholesterol. Reductions in triglycerides and low-density lipoprotein cholesterol tracked closely with placebo outcomes. Pulse rate decreased slightly during the trial, contrasting with the pulse rate increases typically observed with GLP-1 receptor agonists. Other reported signals included anti-petrelintide antibodies in 38% of treated participants—though this showed no apparent effect on weight loss—and alopecia in 5% of treated individuals versus 1% in the placebo group. Three serious adverse events were deemed treatment-related: two cases of cholelithiasis and one case of obstructive pancreatitis. No deaths occurred during the study.
Study authors cautioned against direct cross-trial comparisons, noting that the observed weight loss was similar to the 11.5% reported with cagrilintide after 68 weeks. The trial population was 86% White, only 4% of participants had a baseline body mass index between 27 and 30 kg/m², and dose groups were not masked from one another. Researchers stated that it remains an open question whether amylin-GLP-1 combinations improve tolerability over GLP-1 monotherapy, concluding that amylin-based therapies might have a future as individual as well as combination therapies. Petrelintide is now advancing to phase 3 evaluation.